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Toxicity of human ␣-synuclein when expressed in simple organisms can be suppressed by overexpression of endoplasmic
reticulum (ER)-to-Golgi transport machinery, suggesting that inhibition of constitutive secretion represents a fundamental cause of the toxicity. Whether similar inhibition in mammals represents a cause of familial Parkinson’s disease has not
been established. We tested elements of this hypothesis by expressing human ␣-synuclein in mammalian kidney and
neuroendocrine cells and assessing ER-to-Golgi transport. Overexpression of wild type or the familial disease-associated
A53T mutant ␣-synuclein delayed transport by up to 50%; however, A53T inhibited more potently. The secretory delay
occurred at low expression levels and was not accompanied by insoluble ␣-synuclein aggregates or mistargeting of
transport machinery, suggesting a direct action of soluble ␣-synuclein on trafficking proteins. Co-overexpression of
ER/Golgi arginine soluble N-ethylmaleimide-sensitive factor attachment protein receptors (R-SNAREs) specifically rescued transport, indicating that ␣-synuclein antagonizes SNARE function. Ykt6 reversed ␣-synuclein inhibition much
more effectively than sec22b, suggesting a possible neuroprotective role for the enigmatic high expression of ykt6 in
neurons. In in vitro reconstitutions, purified ␣-synuclein A53T protein specifically inhibited COPII vesicle docking and
fusion at a pre-Golgi step. Finally, soluble ␣-synuclein A53T directly bound ER/Golgi SNAREs and inhibited SNARE
complex assembly, providing a potential mechanism for toxic effects in the early secretory pathway.

INTRODUCTION

␣-Synuclein is a cytosolic neuronal protein whose overexpression or mutation in humans causes Parkinson’s disease
(PD) and involves the selective death of dopaminergic neurons (Cookson and van der Brug, 2008). ␣-Synuclein overexpression in cultured cells has been shown to inhibit mitochondrial function, protein synthesis, proteasome function,
and exocytosis and to induce the unfolded protein response
and oxidative stress (Cookson and van der Brug, 2008).
Although any of these effects on key cellular functions could
cause toxicity, a central problem in these studies is unraveling which effects are a direct result of ␣-synuclein protein
and which arise as a secondary consequence of its harmful
activities. Strategies to ameliorate cellular damage in PD
would ideally target disruptive processes most proximal to
␣-synuclein.
This article was published online ahead of print in MBoC in Press
(http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E09 – 09 – 0801)
on April 14, 2010.
* Present address: Department of Psychiatry, New York University
School of Medicine, 550 First Ave., New York, NY 10016.
Address correspondence to: Jesse C. Hay (jesse.hay@umontana.
edu).
Abbreviations used: ␣-syn, ␣-synuclein; ERES, endoplasmic reticulum exit site; NRK, normal rat kidney; PD, Parkinson’s disease;
SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor.
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The native function of ␣-synuclein in neurons is under
intense investigation. The endogenous protein is present on
the surface of synaptic vesicles in neurons, and its overexpression inhibits vesicle priming for fusion (Fortin et al.,
2005; Larsen et al., 2006; Nemani et al., 2010). Gene knockout
studies support a required role for the endogenous protein
in maintenance of synaptic vesicle pools (Cabin et al., 2002).
A positive role as a chaperone for synaptic vesicle transport
machinery was suggested by genetic interactions with the
cysteine string protein (Chandra et al., 2005). Complicating
matters is the observation that ␣-synuclein is an intrinsically
unfolded protein that accumulates in cytoplasmic polyubiquitinated protein aggregates (Cookson and van der Brug,
2008). Whether these insoluble intracellular aggregates are
causally related to PD is unclear.
A potential breakthrough in understanding ␣-synuclein
toxicity in PD resulted from a high-copy suppressor screen
conducted in yeast (Cooper et al., 2006). ␣-Synuclein overexpression was found to suppress yeast growth, providing
the opportunity to search for genes whose co-overexpression restored viability. Most of the discovered genetic modifiers were trafficking machinery for endoplasmic reticulum
(ER)-to-Golgi transport, including a rab protein, COPII coat
subunits and regulators, and a soluble N-ethylmaleimidesensitive factor attachment protein receptor (SNARE). The
ability of multiple ER-to-Golgi transport proteins to largely
reverse the toxicity of ␣-synuclein overexpression strongly
implied that the cellular pathology was primarily related to
the actions of ␣-synuclein on ER-to-Golgi vesicle transport.
Indeed, ER-to-Golgi transport was blocked in yeast and
© 2010 by The American Society for Cell Biology

␣-Synuclein Inhibits ER-to-Golgi Transport

other processes such as oxidative stress, if affected, were
either not life-threatening to yeast or were secondary results
of the block in vesicle transport. The yeast in which transport was inhibited accumulated massive cytoplasmic aggregates containing ␣-synuclein, transport vesicles, and most of
the cellular pool of ER/Golgi rabs and SNAREs (Gitler et al.,
2008), suggesting a mechanism involving postbudding depletion of transport machinery from their site of function. A
hypothetical mechanism for familial PD was proposed
wherein a primary defect in ER-to-Golgi transport could
selectively cause dopaminergic neuronal death (Cooper et
al., 2006; Gitler et al., 2008). Inadequate delivery of proteins
such as the vesicular monoamine transporter to synaptic
sites could allow dopamine and its by-products to accumulate in the synaptic cytoplasm, causing oxidative stress.
Thus, the inability to properly compartmentalize dopamine
metabolism could selectively kill dopaminergic neurons, although in principle ER-to-Golgi transport would be inhibited in all cells overexpressing ␣-synuclein. However, the
yeast xenogenetic system is a potential concern, and it has
remained untested whether ␣-synuclein targets the mammalian secretory pathway at analogous steps. Furthermore, the
role of large ␣-synuclein aggregates and inclusions such as
those that nonselectively consumed yeast rabs and transport
vesicles (Gitler et al., 2008) is controversial and may represent a downstream consequence as opposed to a cause of
␣-synuclein toxicity (Cookson and van der Brug, 2008). In
addition, many studies of ␣-synuclein toxicity, including
those cited above, use very high overexpression levels that
could in principle induce toxic effects unrelated to the development of the human disease.
Here, we document that relatively mild overexpression of
human ␣-synuclein, wild-type or disease-associated mutants, specifically and potently inhibits ER-to-Golgi transport in mammalian cells, and that overexpression of ER-toGolgi SNAREs reverses this transport inhibition directly, i.e.,
without affecting ␣-synuclein expression, localization, aggregation or disposal. ␣-Synuclein A53T maximally inhibited
transport at low expression levels. The inhibition of ER-toGolgi transport did not involve mistargeting of endogenous
transport machinery, for example into ␣-synuclein-aggregates (Gitler et al., 2008). These findings support a direct
inhibitory action of monomeric or soluble ␣-synuclein oligomers on ER/Golgi transport machinery in its unperturbed
membrane environment. In support of this hypothesis, purified ␣-synuclein protein directly inhibited pre-Golgi COPII
vesicle docking and fusion in vitro. Finally, purified, soluble,
unaggregated ␣-synuclein A53T protein directly bound ER/
Golgi SNAREs and inhibited the in vitro assembly of the
fusogenic ER/Golgi SNARE complex. In cells, overexpression of the arginine (R)-SNARE ykt6 conferred more potent
resistance to ␣-synuclein inhibition than the ER/Golgi RSNARE sec22b.Ykt6 in mammals is expressed at low levels
in most cell types and functions in Golgi- and endosomerelated membrane fusion steps (Zhang and Hong, 2001;
Fukasawa et al., 2004; Tai et al., 2004). Intriguingly, ykt6 is
dramatically overexpressed in neurons and the dopaminergic PC12 cell line (Hasegawa et al., 2003) for unknown reasons, where most of the protein seems to be stored in novel
cytoplasmic particles (Hasegawa et al., 2004). One possibility
is that ykt6’s unique propensity among SNAREs to confer
resistance to secretory insults has a neuroprotective effect,
providing a rationale for its enigmatic overexpression in
neurons.
Vol. 21, June 1, 2010

MATERIALS AND METHODS
Antibodies and Expression Constructs
Mouse monoclonal anti-myc antibodies were purified from hybridoma 9E10
tissue culture supernatants. Mouse monoclonal anti-human ␣-synuclein was
obtained from BD Biosciences (San Jose, CA; catalog no. 610786). Rabbit
polyclonal anti-human ␣-synuclein antibody was obtained from Sigma-Aldrich (St. Louis, MO; catalog no. S3062). Rabbit polyclonal anti-Golgi phosphoprotein of 130 kDa (GPP130) was obtained from Covance Research Products (Princeton, NJ; catalog no. PRB144C). Mouse monoclonal anti-␤galactosidase (␤-gal) antibody was obtained from Developmental Studies
Hybridoma Bank (University of Iowa, Iowa City, IA). Rabbit polyclonal
anti-rat lysosome-associated membrane protein (LAMP)-1 was obtained from
Calbiochem (San Diego, CA; catalog no. 428017). Rabbit polyclonal anti-rab1A
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA; catalog no.
sc-311). Mouse monoclonal anti-LC3 was from MBL (Nagoya, Japan; catalog
no. M152-3). Chicken polyclonal anti-rat ykt6 was developed in our laboratory and described previously (Hasegawa et al., 2003, 2004), as were antibodies against sec22b, rbet1, rsly1, p24, and sec31 (Xu et al., 2000; Xu and Hay,
2004). Chicken polyclonal anti-rat p115 was a kind gift from Dr. Elizabeth
Sztul (University of Alabama-Birmingham, Birmingham, AL). Wild-type
␣-synuclein and A53T constructs in pcDNA 3.1 were a kind gift from Dr.
Diane Hanger (King’s College London, United Kingdom). Rat myc-ykt6 and
mouse myc-sec22b constructs were described previously (Hasegawa et al.,
2003, 2004). Residues 710-3755 encoding ␤-galactosidase in the pSV-␤-galactosidase control vector (Promega, Madison, WI; catalog no. E1081) were
amplified using specific primers including restriction sites for SacII and XbaI.
The polymerase chain reaction (PCR) product was cut using SacII and XbaI
and subcloned into SacII/XbaI-digested pcDNA3.1 encoding an N-terminal
myc epitope to generate the myc-lacZ construct. Syntaxin 5 small interfering RNA (siRNA) oligonucleotide sequences were a kind gift from Dr.
Andrew Peden (Cambridge Institute for Medical Research, Cambridge,
United Kingdom).

Transport Assay
Normal rat kidney (NRK) cells were maintained in DMEM high glucose
containing 10% fetal calf serum and penicillin-streptomycin. Suspensions of
NRK cells were electroporated with 15 g of ␣-synuclein DNA construct; for
rescue experiments, the ␣-synuclein construct was coelectroporated with 15
g of myc-ykt6 or myc-sec22b DNA constructs. Mock-transfected cells were
electroporated with no DNA present. After 48 h of protein expression at 37°C,
the cells were electroporated a second time with 15 g of vesicular stomatitis
virus-glycoprotein-green fluorescent protein (VSV-G-GFP) DNA construct.
They were then grown overnight on poly-l-lysine– coated coverslips at 40°C.
For the 0-min time point, coverslips were directly transferred from 40°C to
fixative. For other time points, coverslips were transferred from 40°C into
six-well chambers containing pre-equilibrated 32°C medium for various intervals and then transferred to fixative. PC12 cells were maintained as described previously (Hasegawa et al., 2003) and seeded at 0.5–1.0 ⫻ 106 cells/
well in six-well plates followed by transfection using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) as per manufacturer’s instructions. Four micrograms of VSVG-GFP DNA was cotransfected with either 4 g of ␣-synuclein
A53T DNA, ␤-gal DNA, or no DNA (“mock”) per well for 8 h. The media
were then replaced with fresh PC12 media and allowed to grow overnight.
After 24 h, the cells were transferred to coverslips in conditioned media and
maintained at 40°C for another 24 h. Transport assays were carried out as
described for NRK cells.

Immunofluorescence Microscopy
Coverslips were fixed with 4% paraformaldehyde containing 0.1 M sodium
phosphate, pH 7.0, for 30 min at room temperature and quenched twice for 10
min with phosphate-buffered saline (PBS) containing 0.1 M glycine. Fixed
cells were treated for 15 min at room temperature with permeabilization
solution containing 0.4% saponin, 1% bovine serum albumin (BSA), and 2%
normal goat serum dissolved in PBS. The cells were then incubated with
primary antibodies diluted in permeabilization solution for 1 h at room
temperature. Next, coverslips were washed three times with permeabilization
solution and incubated 30 min at room temperature with different combinations of fluorescein isothiocyanate (FITC)-, Cy3-, amino-methyl-coumarinacetate (AMCA)-, and/or Cy5-conjugated anti-mouse, anti-rabbit, or antichicken secondary antibodies. After the secondary antibody incubation,
coverslips were again washed three times with permeabilization solution and
mounted on glass slides using Slow Fade Gold antifade reagent (Invitrogen),
and the edges were sealed with nail polish. Slides were analyzed using 40⫻
and 60⫻ objectives on an E800 microscope (Nikon, Tokyo, Japan) with excitation and emission filter wheels (Chroma Technology, Brattleboro, VT), Orca
2 camera (Hamamatsu, Bridgewater, NJ), and Z-drive (Nikon), all automated
using OpenLab 5.0 software (Improvision, Coventry, United Kingdom). For
transport index assays, the images collected for each field of cells were
VSV-G-GFP (FITC filters), ␣-synuclein (AMCA filters), GPP130 (Cy5 filters),
and either ykt6 or sec22b (Cy3 filters).
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Image Analysis and Quantitation
Images for quantitation were collected in a consistent manner with regard to
cell morphology, protein expression levels, and exposure. After choosing a
fixed exposure time for each color channel that would accommodate the
majority of cells, we avoided any cell whose intensity values in any color
exceeded the saturation value of 16383 on our 14-bit acquisition system. We
also avoided capturing cells lacking flat morphology and single, well defined
nuclei surrounded on all sides by an expanse of cytoplasm. Only cells exhibiting relatively high synuclein intensities (approximately the top 25%) were
selected for all the experiments except where different expression levels of
proteins were purposefully used to analyze transport (see Figure 4B). For
quantification purposes, a single widefield image plane was collected for each
color channel for each field of cells randomly encountered containing at least
one qualifying cell. Image deconvolution was not performed. Background in
all quantification images was removed by defining a dark extracellular area of
the image as zero using the automation tool in OpenLab. To ensure unbiased
quantitation, all captured cells meeting the above criteria were assigned
numbers that were associated only with the VSV-G-GFP image. Next, the
marked VSVG-GFP– expressing cells were coded to mask their identity and
isolated from all of the other images that could reveal their condition. After
the transport index parameters were determined in OpenLab, the images
were uncoded and reassembled with matching images from the same fields.
Transport indices were calculated from at least 20 cells per condition.
The Golgi region was defined by GPP130 immunofluorescence: a Golgi
mask was created by thresholding the GPP130 image at 25% of its maximum
value. This was used to identify the Golgi pixels in the associated VSV-G-GFP
image. Transport index was calculated from the VSV-G-GFP image as the
maximum pixel intensity within the Golgi region mask divided by the mean
pixel intensity in the cell periphery. Maximum intensity was used for the
Golgi instead of mean to avoid having to calculate the precise cross-sectional
area of the Golgi, which leads to greater variance. The peripheral fluorescence
in the denominator of the transport index was derived from a sample of the
ER taken by manually drawing an oval-shaped region of interest (ROI) with
the long dimension extending from the edge of the nucleus to roughly the
edge of the cell; the surface of the nucleus on which the ROI abuts was chosen
so as to optimally avoid encompassing or being near any Golgi elements. The
mean pixel intensity for this ROI on the VSV-G-GFP image was the denominator of the transport index. Transport index was calculated for each cell
separately.
To compare the total protein expression levels of quantitated cells, the
boundary of the cell was defined by manually drawing an ROI around the cell
on the ␣-synuclein image. The ROI was then applied to the ␣-synuclein,
VSVG-GFP, ykt6, or sec22b images, and the fluorescence data were collected.
Total staining intensity for a protein was calculated as the product of mean
intensity and the area of the ROI. In experiments to purposefully correlate
transport index with protein expression levels, images were collected of cells
having different fluorescence intensity levels by using a single exposure time;
after calculation of transport indices as usual, total staining intensity was
calculated, and the cells were organized into two or more intensity bins.
To quantify induction of LC3, NRK cells were transfected with the
␣-synuclein (A53T) construct and allowed to express the protein for 48 h.
Serum-starved cells (the positive control for induction) were obtained by
growing the cells in serum-free DMEM for 4 h before fixation. Cells were fixed
and processed for immunofluorescence using the usual protocol, with rabbit
polyclonal anti-␣-synuclein antibody (Sigma-Aldrich), mouse monoclonal
anti-LC3 antibody, and their respective Cy3- and FITC-conjugated secondary
antibodies. Mock and serum-starved cells were chosen at random for image
capture. A53T-transfected cells were chosen by looking in the Cy3 channel to
find strong A53T-expressing cells. Image stacks containing 21 planes in the
FITC channel were taken for each cell in 0.2-m increments and deconvolved
using Huygens software. One image plane near the image center was selected
for quantitation. The background in these cells was subtracted by setting a
dark extracellular area in the field to zero by using the automation tool in
OpenLab software. LC3 objects were identified and counted using a binary
mask generated by thresholding LC3 labeling at 4 times the cytosolic background intensity in the cell. Twenty cells were counted in each condition.

Triton X-100 Insolubility Assay
NRK cells were transfected with the ␣-synuclein A53T DNA construct as
usual. After 2 days of protein expression, the cells were harvested in cold lysis
buffer (150 mM NaCl, 50 mM Tris, pH 7.6, and 2 mM EDTA, with protease
inhibitors) containing 1% Triton X-100. The lysate was mixed end-over-end
for 30 min and then centrifuged at 10,000 ⫻ g for 15 min at 4°C. The
detergent-insoluble pellet was then washed twice in PBS and dissolved in SDS
sample buffer. The detergent soluble supernatant was briefly sonicated and
adjusted to 1⫻ SDS sample buffer. Equal proportions (1%) of detergentresistant and -soluble fractions were resolved on a 15% acrylamide gel and
immunoblotted.

Expression Analysis by Flow Cytometry
NRK cells were electroporated with ␣-synuclein A53T in pcDNA 3.1 and cells
were grown to express the protein for 2 d. Mock-transfected cells were

1852

electroporated in the absence of plasmid DNA. Cells were trypsinized, resuspended, and washed three times with PBS. The cells were then fixed,
quenched, permeabilized, and immunolabeled as described above for immunofluorescence microscopy except that reagent changes and washes involved
centrifugation and resuspension. Secondary antibodies used were FITC-conjugated anti-mouse antibody for detecting ␣-synuclein and phycoerythrin
(PE)-conjugated anti-rabbit antibody for detecting rbet1, membrin, syntaxin 5,
and sec22b. Labeled NRK cells were analyzed using an FACSCalibur flow
cytometer (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR).
Cells were gated consistently on forward and side scatter properties to
exclude damaged cells or debris from our data. Labeling with only the
secondary antibodies was used as a negative control to ensure that specific
labeling for each antigen was present.

Endoglycosidase H (Endo H) Resistance Acquisition Assay
To express the model cargo and potential transport inhibitors with a cotransfection efficiency necessary for analysis in cell lysates, we electroporated NRK
cells with constructs for VSV-G-myc and either ␤-galactosidase, ␣-synuclein
A53T, or empty pcDNA3.1 vector at a 1:2 mass ratio. Unlike in the NRK
microscopy assays (see Figures 1– 6), we could not introduce the two vectors
by using sequential transfections, thus allowing several days of ␣-synuclein
expression (the cotransfection efficiency of that procedure was too low for
lysate experiments and VSV-G-myc was too toxic to introduce ⬎24 h before
assay). After 24 h postelectroporation at 37°C, we infected the cells with
vaccinia virus vTF7 (Fuerst et al., 1986; Dascher et al., 1995; Xu and Hay, 2004)
for 4 – 6 h, yielding an approximately threefold amplification of ␤-galactosidase and ␣-synuclein beyond preinfection levels (data not shown). This
amplification was necessary to partially offset the shorter expression time and
the less-than-optimal coexpression levels compared with the microscopy
experiments, in which NRK cells expressed ␣-synuclein for 3 d before assay,
the cotransfection efficiency of chosen cells was 100%, and only robustly
expressing cells were included in the analysis. After shift to 32°C for varying
periods, cells were lysed with 0.1 M citrate, pH 5.5 (NaOH), 0.1% SDS, 0.8%
␤-mercaptoethanol, and protease inhibitors; incubated at 95°C for 3 min; and
centrifuged at 100,000 ⫻ g for 20 min. Thirty microliters of the supernatants
was incubated or not with 5 U of endo H (Roche Diagnostics, Indianapolis,
IN) for 16 –24 h at 37°C before SDS-polyacrylamide gel electrophoresis
(PAGE) analysis and immunoblotting using an anti-myc antibody. The endo
H-sensitive (GS) and endo H-resistant (GR) band ratio was captured in a linear
range with an LAS-3000 imager (Fujifilm, Tokyo, Japan) for chemiluminescence and quantitated using ImageGauge software (Fujifilm).

Homotypic COPII Vesicle Fusion Assay
COPII vesicle fusion experiments were carried out as described previously
(Xu and Hay, 2004; Bentley et al., 2006; Cai et al., 2007). In brief, the VSV-Gmyc– expressing NRK cells and pulse-radiolabeled VSV-G*-containing cells
were permeabilized by scraping with a rubber policeman and then washed
and resuspended at ⬃170 l/10-cm plate in 50/90 buffer (50 mM HEPES, pH
7.2, 90 mM potassium acetate). A first-stage (vesicle release) incubation to
produce enough vesicles for a 24-point fusion assay contained 1.96 ml and
consisted of 432 l of water, 67.5 l of 0.1 M magnesium acetate, 135 l of
ATP-regenerating system, 40.5 l of 1 M HEPES, pH 7.2, 270 l of weak
calcium buffer (20 mM HEPES, pH 7.2, 1.8 mM CaCl2, and 5 mM EGTA), 675
l of dialyzed rat liver cytosol, and 337.5 l of either of the permeabilized cell
populations. After incubation at 32°C for 30 min to allow vesicle release, cells
were removed by centrifugation at 4000 ⫻ g for 1 min followed by 15,000 ⫻
g for 1 min. The supernatant, which contains released COPII vesicles, was
saved. For the second-stage fusion incubations, each reaction totaled 200 l
and contained 72.5 l of VSV-G-myc vesicles, 72.5 l of VSV-G* vesicles, and
55 l of 25/125 buffer or purified test proteins extensively dialyzed in 25/125
buffer. After a 60-min preincubation on ice with these test components, the
reactions were incubated at 32°C for 60 min to allow tethering, fusion, and
heterotrimerization between VSV-G-myc and VSV-G* vesicles. For measuring
heterotrimers, the final vesicle suspensions were supplemented with 2%
Triton X-100, incubated with agitation at 4°C for 20 min and then centrifuged
at 100,000 ⫻ g for 30 min. The 100,000 ⫻ g supernatants containing solubilized
VSV-G trimers were then processed for immunoprecipitation by using 5 g of
biotinylated anti-myc antibodies and 5 l (packed) streptavidin-Sepharose
(GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). Immunoprecipitates were solubilized in SDS sample buffer, analyzed by SDS-PAGE
(8%) and phosphorimaging, and coprecipitated VSV-G* was quantified.
Full-length human ␣-synuclein A53T was subcloned into pGEX-KG, expressed as a glutathione transferase (GST) fusion protein, purified, and
cleaved using a protocol similar to that for GST-rbet1 (Xu et al., 2000). This
protein was abundant and soluble when expressed at 37°C, and solubility
issues were not encountered during purification and storage. For in vitro
fusion assays, GST and GST/␣-synuclein (syn) A53T test proteins were prepared in the absence of any detergents. GST-␣-synuclein was cleaved free of
GST with thrombin, which was then deactivated with phenylmethylsulfonyl
fluoride before extensive dialysis in 25/125 buffer and assay.
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Figure 1. ␣-Synuclein A53T delays and mycykt6 restores ER-to-Golgi Transport. (A) Representative epifluorescent images from several
incubation time points displaying VSV-G-GFP
and GPP130 in the same cells. The top row of
cells were electroporated with buffer only and
the bottom row were electroporated with an
siRNA for syntaxin 5. (B) Quantitation of transport employing at least 20 randomly chosen cells
from each condition (see Materials and Methods).
(C) Representative images of cells from 12 min at
32°C on separate coverslips singly transfected
with VSV-G-GFP (top row), doubly transfected
with VSV-G-GFP and ␣-synuclein A53T (middle
row), and triply transfected with VSV-G-GFP,
␣-synuclein A53T, and myc-ykt6 (bottom row).
Golgi staining with GPP130 is shown for each
cell. (D) Quantitation of the experiment in C.
Error bars represent SEs.

Solution SNARE Assembly and Bead Binding Experiments
Soluble constructs containing the full cytoplasmic domains of syntaxin 5,
rbet1 and sec22b, and full-length membrin protein, were expressed in Escherichia coli, extracted, renatured, and purified as detailed previously (Xu et al.,
2000). All purified proteins were dialyzed into buffer A (20 mM HEPES, pH
7.2, 0.15 M KCl, 2 mM EDTA, and 5% glycerol) and stored at ⫺80°C in the
presence of 1 mM dithiothreitol, 4 g/ml aprotinin, 2 g/ml leupeptin, and
1 g/ml pepstatin A. For SNARE assembly reactions, 600 pmol of each of the
four ER/Golgi SNAREs and a threefold molar excess of purified GST or
GST/␣-syn A53T were combined to make up 300-l SNARE assembly reactions with each SNARE at 2 M, plus 0.1% Triton X-100. After 4 h on ice, the
mixture was fractionated on a 24-ml Superdex 200 column, and the fractions
were processed as described previously (Xu et al., 2000). Because the overexpression studies suggested a directly antagonistic relationship between
␣-synuclein and R-SNAREs, we preincubated sec22b with GST or GST/␣-syn
alone on ice before adding the other SNARES. GST and GST/␣-syn A53T
preparations at the proportions used are shown in Figure 9F.
Bead binding studies also were carried out as detailed previously (Xu et al.,
2000). For testing SNARE binding to ␣-synuclein (see Figure 9, A and B),
crude bacterial lysates expressing GST or GST-␣-syn A53T were mixed with
glutathione-Sepharose at 4°C so as to nearly saturate the binding capacity.
Then, they were washed extensively and stored as a 50% bead suspension in
the refrigerator until use in a binding study. A typical bead binding reaction
consisted of 20 l of 50% glutathione-Sepharose beads containing 124 pmol
(620 nM) of immobilized protein and 20 –200 pmol (100 nM to1 M) of soluble
binding partners in a final volume of 200 l also containing 0.1% Triton X-100
and 0.1% BSA. After 1 h at 4°C with constant agitation, beads were washed
three times with buffer A plus 0.1% BSA before solubilization of the bound
proteins in SDS-PAGE sample buffer. For testing syntaxin 5 binding to membrin beads in the presence or absence of ␣-synuclein (see Figure 9, C and D),
bacterial lysates expressing GST or GST-membrin were prepared as described
above. Both the beads and soluble binding partner were preincubated with
GST or GST/␣-synuclein A53T for 4 h at 4°C. The preincubated beads and
soluble binding partner were then combined to a final volume of 200 l
containing 20 l of 50% beads; 14 M GST or GST/␣-synuclein A53T; and 0.2,
0.5, or 1 M soluble syntaxin 5 plus detergent and BSA. Syntaxin-5 binding
was then determined as described above.

RESULTS
A Morphological ER-to-Golgi Kinetics Assay
To test the hypothesis that ␣-synuclein inhibits ER-to-Golgi
transport in mammalian cells, we developed a fluorescencebased assay for the transport of vesicular stomatitis virus
glycoprotein (VSV-G ts045) in intact cells. NRK cells were
electroporated with pcDNA3.1-VSV-G-GFP ts045 and incubated at 40°C for 18 h to accumulate cargo in the ER. Coverslips of NRK cells were shifted to 32°C for varying times,
and then the cells were fixed and imaged by widefield
Vol. 21, June 1, 2010

fluorescence microscopy. In the first experiment, the coverslips were held at 10°C for 1 h immediately preceding the
shift to permissive temperature; 10°C allows VSV-G to fold
and enter ER exit sites (ERES) but does not allow budding
(Mezzacasa and Helenius, 2002). As shown in Figure 1A, the
mostly ER pattern of VSV-G-GFP gave way to an increasing
concentration in the Golgi over a 7-min time period at 32°C.
NRK cells previously electroporated with an siRNA to syntaxin 5, a glutamine (Q)A-SNARE required for ER-to-Golgi
transport (Rowe et al., 1998; Xu and Hay, 2004), developed
little perinuclear concentration, indicating that transport
was largely blocked (Figure 1A). Supplemental Figure S1A
establishes depletion of syntaxin 5 from the entire cell population. To quantify transport, we calculate a simple transport index ratio that compares fluorescence intensity in the
Golgi area to that in the peripheral cytoplasm, representing
the ER (see Materials and Methods). A transport index of
slightly above 1.0 is expected if no accumulation of VSV-GGFP in the Golgi occurred relative to that in peripheral
structures. As shown in Figure 1B, the transport index of
VSV-G-GFP rose from ⬃2 to more than ⬃12 during 7 min in
cells that did not receive siRNA (solid diamonds), but it rose
only to ⬃6 in cells depleted of syntaxin 5 (open squares).
Thus, our algorithm reports a highly significant inhibition of
transport (70% inhibited at 3 min), after depletion of an
established ER/Golgi SNARE. For the remaining experiments, we skipped the 10°C step. As shown in Figure 1D
(solid diamonds), the lack of preincubation lowered the
starting transport index to ⬃1.0 and resulted in slightly
lower maximal transport values achieved over a longer time
course, demonstrating that our method can detect a shift in
transport kinetics between two cell populations each capable
of full transport. In our standard assay (Figure 1D), the
transport index rose nearly 10-fold over a 30-min incubation
at 32°C.

␣-Synuclein A53T Delays ER-to-Golgi Transport in
Mammals
To test whether a PD-associated mutant of ␣-synuclein affects ER-to-Golgi transport, we electroporated NRK cells
with pcDNA3.1 encoding human ␣-synuclein A53T. Two
days later, the cells were electroporated with VSV-G-GFP,
1853
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Figure 2. Restoration of ER-to-Golgi transport is specific for coexpression of myc-ykt6
and ␣-synuclein. (A) NRK cells coexpressing
myc-␤-galactosidase did not exhibit restored
transport. (B) Immunoblot of NRK cell lysates
using anti-myc antibody. (C) Scatter plot showing every individual cell from the experiment
in part A, as a function of VSV-G-GFP expression and transport index. (D) Transport
indices of NRK cells electroporated with either ␣-synuclein A53T or myc-ykt6 alone (not
coexpressed) shows that myc-ykt6 does not itself
accelerate transport. Error bars represent SEs.

and the transport assay was performed. As shown in Figure
1C, cells expressing ␣-synuclein (middle row) displayed less
VSV-G-GFP in the Golgi area and retained greater fluorescence in the periphery compared with mock-electroporated
cells (top row). As shown in Figure 1D (solid diamonds vs.
open squares), the transport index was inhibited by ⬃40%
after 12 min. We also examined the individual intensity
parameters that make up the transport index, and we found
that ␣-synuclein A53T inhibited Golgi as well as enhanced
peripheral fluorescence (Supplemental Figure S1B), as expected. This eliminates most potential artifacts whereby
Golgi or cell size/shape could affect transport index. We
noted no cytopathic effects of A53T expression by using the
pcDNA3.1 vector for several days. ␣-Synuclein expression in
these studies is relatively low. The immunoblot in Supplemental Figure S1C demonstrates that our transiently transfected NRK cells express ⬃80% more ␣-synuclein than
present in a comparable protein load of total rat brain lysate.
Given our transfection efficiency of ⬃40%, we estimate that
transfected cells express ␣-synuclein approximately threefold higher than the average cell in a rat brain.
Ykt6 Coexpression Partially Restores Transport
If the inhibition was a direct result of interference with
ER/Golgi transport machinery, then overexpression of ER/
Golgi machinery might rescue transport. Ykt6p was the only
SNARE multicopy suppressor of ␣-synuclein A53T toxicity
in yeast (Cooper et al., 2006). pcDNA3.1 encoding rat mycykt6 was coelectroporated with ␣-synuclein A53T and evaluated using the transport assay. As shown in Figure 1C,
bottom row, cells expressing both ␣-synuclein A53T and
myc-ykt6 had similar VSVG-GFP fluorescence to cells lacking ␣-synuclein A53T (top row, mock). The transport index
was ⬃70% restored in this experiment (Figure 1D); however,
the degree of restoration in other experiments varied between 50 and 80% of mock values. Analysis of the individual
intensity parameters revealed that ykt6 coexpression in1854

creased fluorescence in the Golgi as well as decreased peripheral fluorescence (Supplemental Figure S1B).
We wondered whether coexpression of myc-ykt6 might
influence the expression of ␣-synuclein A53T to lower its
toxicity. First, we created an analogous pcDNA3.1 construct encoding myc-␤-galactosidase. Coexpression of this
construct with ␣-synuclein A53T, in contrast to myc-ykt6,
was found to have no affect on transport index (Figure 2A).
Myc-ykt6 and myc-␤-galactosidase were expressed at
roughly comparable levels according to immunoblotting using anti-myc antibody (Figure 2B). Restoration is thus specific to myc-ykt6. Furthermore, any affects of myc-ykt6 on
total ␣-synuclein expression, as measured by staining intensity, do not account for its restoration of transport (Figure
3B; described below). Another possibility was that ykt6 coexpression might affect the VSV-G-GFP expression and that
VSV-G-GFP load affects the transport index. As shown in
Figure 2C, myc-ykt6 – expressing cells’ transport indices
were higher over the entire range of VSV-G-GFP. Finally, we
wondered whether ykt6 coexpression might generally accelerate ER-to-Golgi transport as opposed to specifically restore. As shown in Figure 2D, myc-ykt6 expression by itself
did not significantly affect transport kinetics. We conclude
that ykt6 specifically restores ER-to-Golgi transport to
␣-synuclein A53T-intoxicated cells, independently of affects
it may have on ␣-synuclein and VSV-G-GFP expression
patterns.
Sec22b Restores Transport but Less Effectively Than ykt6
In nonneuronal cells, ykt6 is required for transport between
the Golgi and endosome (Tai et al., 2004), intra-Golgi transport (Fukasawa et al., 2004), and a late step in ER-to-Golgi
transport (Zhang and Hong, 2001). Blockage of the ykt6dependent step(s) in the biosynthetic secretory pathway results in VSV-G concentration at the Golgi and concomitant
depletion from the periphery (Zhang and Hong, 2001).
Hence, our transport index would not report a block at the
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Figure 3. Ykt6 rescues transport more potently than sec22b. (A) Comparison of transport rescue by myc-sec22b and myc-ykt6. (B) Scatter
plot showing every cell from the experiment in A, as a function of total cellular ␣-synuclein A53T staining intensity and transport index.
(C) A separate experiment from part A, in which a wide intensity range of myc-sec22b coexpressing cells was imaged, binned according to
anti-myc intensity, and transport indices calculated. (D) Another experiment in which anti-myc staining intensities were binned and transport
indices plotted for myc-ykt6 and myc-sec22b coexpressing cells. (E) Total anti-myc staining intensities for the bins of cells analyzed in D.
(F) Anti-myc immunoblot of NRK cell lysates of duplicate coverslips to those analyzed in D and E. The statistical significance of differences
between the indicated mean transport indices are reported as p values from a two-tailed Student‘s t test. Error bars represent SEs.

ykt6-dependent step and ␣-synuclein A53T, which causes
VSV-G to fail to concentrate at the Golgi (Figure 1), must
inhibit at earlier step(s) in ER-to-Golgi transport. Early membrane fusion steps in ER-to-Golgi transport are mediated by
a quaternary SNARE complex composed of syntaxin 5,
membrin, rbet1, and sec22b (Rowe et al., 1998; Xu et al., 2000;
Xu and Hay, 2004). Sec22b is the closest paralogue of ykt6;
both are R-SNAREs that fill the structural role of VAMP in
SNARE bundles (Hay, 2001) and possess longin domains
serving targeting/regulatory functions (Rossi et al., 2004). In
yeast, loss of SEC22 can be compensated for by YKT6 overexpression (Liu and Barlowe, 2002). We coelectroporated
NRK cells with ␣-synuclein A53T together with either mycsec22b or myc-ykt6 in pcDNA3.1 and compared restoration.
As shown in Figure 3A, myc-sec22b restored transport approximately half as well as myc-ykt6. We wondered whether
either coexpression construct affected ␣-synuclein A53T expression and whether this could explain their differing abilities
to rescue. As shown in Figure 3B, in any given synuclein
staining intensity range, ykt6-cotransfected cells displayed
higher transport indices. In this experiment, the imaged cells
exhibited ⬃75% more total anti-myc staining in the mycsec22b population than in the myc-ykt6 population (data not
Vol. 21, June 1, 2010

shown). One possibility was that myc-ykt6 restores transport significantly more potently than myc-sec22b; alternatively, myc-sec22b might inhibit transport at high levels of
expression but potently restore transport only when expressed at low levels. We therefore imaged an experiment
over a wide range of myc-sec22b expression levels, including some low expressers that would have been avoided
above. As shown in Figure 3C, when all of the cells were
binned into low, medium, and high expression of mycsec22b based upon total anti-myc staining intensity, increasing myc-sec22b expression correlated with higher restoration of transport, reaching a maximum at ⬃50% restoration
in the highest expressing population. We conclude that mycsec22b progressively restored transport in a dose-dependent
manner. To directly compare myc-sec22b and myc-ykt6 rescue abilities semiquantitatively, we performed another experiment and imaged cells coexpressing ␣-synuclein A53T
and myc-ykt6 or myc-sec22b over widely overlapping antimyc staining intensities. In Figure 3D, the anti-myc total
staining intensity exhibited by myc-ykt6 and myc-sec22b is
segregated into “low” and “high” bins. The mean staining
intensities were nearly identical for the two constructs in
each bin (Figure 3E). However, in either the low- or high1855
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Figure 4. Wild-type ␣-synuclein delays transport to the same degree, but less potently than
A53T. (A) Time course of ER-to-Golgi transport
in NRK cells electroporated with wild-type or
A53T ␣-synuclein. Only cells showing strong
(approx. top quartile) anti-␣-synuclein staining
were imaged. (B) A separate experiment in
which a wider range of anti-␣-synuclein staining
intensities were imaged, cells were separated
into intensity bins as shown on the x-axis, and
their transport indices plotted. Both the 12-min
and 0-min timepoints are plotted for mocktransfected cells along the y-axis (values of
⬃8.5 and ⬃1.2, respectively). (C) Coexpression
of myc-ykt6 partially restores transport inhibition caused by wild-type ␣-synuclein. In some
instances, the statistical significance of differences between the indicated mean transport
indices are reported as p values from a twotailed Student‘s t test. Error bars represent SEs.

intensity bin, myc-ykt6 restored transport to a greater degree than myc-sec22b. Importantly, myc-ykt6 restored transport almost equally well in the high and low bin, whereas
myc-sec22b restored transport significantly more in the
higher bin. Although ykt6 and sec22b share the same domain structure, we could not be certain that the two proteins
performed equally for immunostaining. However, immunoblots on the SDS-denatured antigens should provide a more
direct comparison. As shown in Figure 3F, when parallel
coverslips from this experiment were lysed and immunoblotted, it seemed that myc-sec22b was expressed at least
fivefold higher than myc-ykt6, implying that the immunofluorescence signal overestimates myc-ykt6 expression relative to myc-sec22b; in other words, myc-ykt6 is even more
relatively potent compared with myc-sec22b than implied in
Figure 3D. We conclude that myc-ykt6 restores transport
significantly more potently than myc-sec22b, even though
the transport inhibition seems to involve sec22b-dependent
stage(s) in ER-to-Golgi transport.
Wild-Type ␣-Synuclein Inhibits Transport Less Potently
PD can be caused by a dominant mutation or by overexpression of the wild-type allele (Cookson and van der Brug,
2008). Thus, if the inhibition of ER-to-Golgi transport is a
fundamental cause of PD, we would predict that wild-type
␣-synuclein should exhibit the same inhibitory properties,
but only at higher concentrations. We electroporated NRK
cells with A53T or wild-type ␣-synuclein and tested transport kinetics. As shown in Figure 4A, when using our typical
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selection criteria, we detected no difference between the
transport kinetics of wild-type– and A53T-expressing cells;
both were delayed ⱖ50%. We wondered, however, whether
the inhibition of transport may have already reached a maximal value. To examine this, we purposefully imaged cells
expressing very wide ranges of ␣-synuclein expression, including the lowest expressing cells we could confidently
qualify as transfected, and we binned cells according to their
synuclein staining intensity. As shown in Figure 4B, lower
expression levels of wild-type ␣-synuclein were associated
with minimal inhibition of transport and the degree of inhibition increased with increasing staining intensity. However, ␣-synuclein A53T inhibited almost as completely at
low as at high expression levels, indicating that this construct affects the ER/Golgi transport machinery more potently than the wild type. Note that many ␣-synuclein A53Ttransfected cells, perhaps even the majority, fell below the
lowest intensity bin in Figure 4B; if we had been able to
confidently assign these cells as transfected and obtain transport values, we expect we would also have seen a dosedependent titration, but left-shifted relative to wild type. As
shown in Figure 4C, inhibition of transport by high levels of
wild-type ␣-synuclein were rescued by coexpression with
ykt6, to a similar degree as inhibition by A53T (Figures 1–3).
Inhibition Does Not Involve Mistargeting nor Instability
of Transport Machinery
In yeast overexpressing ␣-synuclein A53T, large aggregates
formed containing ␣-synuclein, ER-derived vesicles, endogMolecular Biology of the Cell
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Figure 5. Subcellular distributions of ␣-synuclein A53T, coexpressed myc-ykt6,
and the unperturbed endogenous cellular transport machinery. (A) Comparison
between ␣-synuclein A53T and myc-ykt6 staining patterns. (B) Comparison of
␣-synuclein A53T and endogenous LAMP-1. Blue arrowheads highlight a few of
the ␣-synuclein-positive particles that are positive for LAMP-1. (C) Comparison
of ␣-synuclein A53T and endogenous rab1. (D) Comparison of ␣-synuclein A53T and
endogenous GPP130. In each block shown, green asterisks mark the nucleus of an
␣-synuclein A53T-expressing cell and red asterisks mark the nucleus of an untransfected cell for comparison. Shown are individual focal planes of deconvolved widefield images. (E) A53T-transfected NRK cells were extracted with cold 1% Triton
X-100 and centrifuged at 10,000 ⫻ g for 15 min to generate a supernatant and pellet.
Equal proportions of these fractions were analyzed by SDS-PAGE and immunoblotting for ␣-synuclein and caveolin, a protein known to be in detergent-resistant membrane domains.

enous ER/Golgi SNAREs and rabs (Gitler et al., 2008), suggesting a mechanism whereby transport machinery and secretory membranes could be depleted and their functions’
disrupted. In NRK cells, ␣-synuclein A53T exhibited punctate structures as well as diffuse cytosolic staining (Figure 5,
A–D). The diffuse cytosolic staining varied in intensity relative to the particles. We do not know whether the particulate ␣-synuclein is present in protein aggregates. However,
all ␣-synuclein immunofluorescence staining was extracted
by 0.05% Triton X-100 treatment before fixation (data not
shown), and all ␣-synuclein protein detectable by immunoblotting was found in the soluble fraction of a cold 1% Triton
X-100 total extract of NRK cells (Figure 5E). These results
indicate that any aggregation, if present, had not yet progressed to detergent resistance. The lack of large or detergent-insoluble aggregates under our conditions indicates
that such species are not required to achieve the 40 –50%
delay in ER-to-Golgi transport.
Vol. 21, June 1, 2010

The majority of ␣-synuclein A53T particles were positive
for LAMP-1, but only a fraction of LAMP-1– containing particles were positive for synuclein, consistent with the
␣-synuclein being associated with specialized lysosome-associated organelles, e.g., autolysosomes (Figure 5B). We
noted an amplification of synuclein particles upon addition
of the autophagy inhibitor 3-methyl adenine (3-MA; Supplemental Figure S2, A and B) (Webb et al., 2003), consistent
with a relationship of the ␣-synuclein particles to the autophagic degradation pathway. In addition, transfection with
␣-synuclein A53T caused induction of the early autophagosome marker LC3 (Supplemental Figure S2C). In contrast,
LC3 was only rarely present on the structures positive for
A53T by immunofluorescence (Supplemental Figure S3D).
One possibility consistent with the data are that degradation
of ␣-synuclein occurs by a macroautophagic pathway but
that ␣-synuclein only becomes concentrated significantly in
autolysosomes, a membranous structure no longer positive
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for LC3 (Kabeya et al., 2000; Tanida et al., 2004). However, we
also cannot eliminate the possibility of chaperone-mediated
autophagy (Vogiatzi et al., 2008); the exact route(s) by which
␣-synuclein concentrates in LAMP-positive structures under
our conditions is still an open question.
It was important to establish whether rescue of ER-toGolgi transport by coexpression with myc-ykt6 affected the
targeting of ␣-synuclein. As shown in Figure 5A, myc-ykt6
in NRK cells exhibited a largely cytoplasmic localization. In
the cells overexpressing myc-ykt6, no change in the abundance or size of ␣-synuclein particles was apparent compared with cells only overexpressing A53T (Figure 5, A vs.
B–D). Together with the analysis indicating that myc-ykt6
overexpression did not restore transport by altering
␣-synuclein expression level (Figure 3B), these findings suggest that myc-ykt6 does not restore transport by modulating
␣-synuclein A53T expression, aggregation, or disposal and
favors a direct mode of function whereby a small portion of
myc-ykt6 inserts into quasi-functional secretory membranes
and restores function by acting as a SNARE.
Under the conditions in which ␣-synuclein inhibited ERto-Golgi transport, we observed no colocalization of endogenous SNAREs with the ␣-synuclein A53T particles, as exhibited by the distributions of sec22b (Supplemental Figure
S3A) and rbet1 (data not shown). In contrast to the situation
in yeast (Gitler et al., 2008), the distribution of the ER-toGolgi rab1A protein was unchanged by ␣-synuclein A53T
expression (Figure 5C, compare rab1A distribution in cells
marked with red vs. green asterisks), and the rab was not
detectable in the ␣-synuclein particles (Figure 5C, merged
panel). Furthermore, the Golgi structure remained compact:
we saw no trend toward disruption of the GPP130, p115, or
p24 patterns in ␣-synuclein A53T-overexpressing cells (Figure 5D and Supplemental S3, C and D), in contrast to the
Golgi dispersal caused by knockdown of syntaxin 5 (Figure
1A) and viral overexpression of A53T (Gosavi et al., 2002).
The previously observed Golgi disruption must therefore
have been a downstream consequence rather than a primary
cause of traffic disruptions. Finally, ERES marked by sec31
were not altered and sec31 was not present in synuclein
particles (Supplemental Figure S3B). Because we never
noted colocalization between ␣-synuclein A53T particles
and endogenous ER/Golgi transport machinery, it seems
likely that the soluble form of ␣-synuclein A53T is responsible for the inhibition. Furthermore, we conclude that
␣-synuclein A53T inhibited the transport machinery in situ
and did not involve depletion, mistargeting, nor co-aggregation of transport machinery with the inhibitor.
The antagonistic relationship between A53T and ER/
Golgi SNAREs led us to question whether A53T altered
SNARE expression levels in intoxicated cells. Although no
obvious effects on expression were noticed in the localization studies described above for sec22b and rbet1, we examined expression levels comprehensively for all four ER/
Golgi SNAREs by using intracellular immunofluorescence
labeling quantified by flow cytometry. As shown in Figure 6,
A–D, there was no significant change in sec22b, rbet1, syntaxin
5, or membrin labeling intensity upon expression of A53T,
even in cells expressing high levels of the offensive protein. The
geometric mean labeling intensity was in fact slightly higher for
all four SNAREs in transfected cells compared with the nontransfected cells in the same population. However, this very
small nonspecific increase in SNARE expression also can be
observed in control GFP transfections (data not shown), presumably because there is a slight positive correlation between
individual cells’ robustness of general protein expression and
their transfectability. We conclude that the effect of ␣-synuclein
1858

Figure 6. ␣-Synuclein A53T overexpression does not significantly
affect the expression of ER/Golgi SNAREs. Electroporated NRK
cells were allowed to express the ␣-synuclein A53T construct for 2 d
before fixation, permeabilization, and immunofluorescence labeling
of ␣-synuclein (with FITC) and each ER/Golgi SNARE (with PE).
Labeled cell suspensions were analyzed by flow cytometry. Dot
plots display relationship between ␣-syn A53T labeling and labeling
for syntaxin 5 (A), sec22b (B), rbet1 (C), and membrin (D), where the
frequency of cells with similar labeling intensities is indicated by
color warmth. (E) Mock-transfected cells in which primary antibodies were omitted. (F) Mock-transfected cells labeled with anti-␣synuclein and anti-syntaxin 5 antibodies.

on ER-to-Golgi transport is not due to changes in ER/Golgi
SNARE localization, expression, or stability during the time
frame of our experiments.

␣-Synuclein A53T Inhibits ER-to-Golgi Transport in
Neuroendocrine Cells
To test whether ␣-synuclein A53T overexpression would
inhibit ER-to-Golgi transport in cells with a more neuronal
phenotype, we applied the same transport assay to PC12
cells, a rat dopaminergic neuroendocrine cell line frequently
used in studies of ␣-synuclein toxicity (Cookson and van der
Brug, 2008, and references therein). Chromaffin cells highly
express endogenous ␣-synuclein, whereas the chromaffin
derivative PC12 cell line expresses much lower levels
(Larsen et al., 2006). As shown qualitatively in Figure 7A,
VSV-G-GFP in mock-transfected cells had transitioned from a
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Figure 7. ␣-Synuclein expression retards ER-to-Golgi transport in neuroendocrine PC12 cells. (A) Representative epifluorescent images from
15 min at 32°C, displaying VSV-G-GFP, GPP130, and either ␣-synuclein A53T or ␤-gal driven by pcDNA3.1 transfection. (B) Quantitation of
transport employing at least 20 randomly chosen cells from each condition (see Materials and Methods). Bars represent SEs and are shown only
when exceeding symbol size. The statistical significance of differences between the A53T and mock transport indices at the indicated time
points are reported as p values from a two-tailed Student‘s t test.

primarily peripheral ER localization at 40°C to a punctate juxtanuclear localization that coincided with a Golgi marker by 15
min of incubation at 32°C. Furthermore, a similar transition
was observed in PC12 cells overexpressing ␤-galactosidase. In
contrast, PC12 cells overexpressing ␣-synuclein A53T showed
relatively less accumulation of VSV-G-GFP in Golgi elements
and a greater retention of fluorescence in the periphery. Quantitation of the transport index from PC12 cells randomly chosen
from these populations is shown in Figure 7B. In mock- and
␤-galactosidase–transfected cells, the transport index rose
from ⬃1 to ⬃8 in 15 min at 32°C. In ␣-synuclein A53Ttransfected cells, however, there was an ⬃30% inhibition of
transport, such that a transport index of ⬃6 was reached in
the same incubation time. The ⬃30% retardation of transport
by ␣-synuclein was highly statistically significant at the
three time points tested. These results demonstrate that
␣-synuclein A53T inhibition of ER-to-Golgi transport is a
feature of neuroendocrine cells and is therefore not unique
to nonneuronal cells. In contrast, nonneuronal cells such as
NRK may represent a sensitized system for ␣-synuclein
intoxication of the secretory pathway because the smaller
degree of inhibition in PC12 cells, 30% as opposed to 50%,
indicates that PC12 cells may possess factors or mechanisms
that naturally guard against ␣-synuclein. One of these factors may be ykt6; ykt6 is expressed at particularly high levels
in PC12 cells and neurons (Hasegawa et al., 2003), and we
have shown it to be protective against ␣-synuclein in NRK
cells (Figures 1–3).

␣-Synuclein A53T Directly Inhibits ER-to-Golgi Transport
by Blocking COPII Vesicle Tethering and Fusion at a
Pre-Golgi Step
To further establish the effects of ␣-synuclein expression on
early secretory traffic, we first confirmed the morphological
effects (Figures 1–7) in transfected cells by monitoring the
rate of transition of VSV-G-myc from its endo H-sensitive to
its endo H-resistant form. Due to technical limitations (see
Materials and Methods for details), we changed our transfection conditions; both VSV-G-myc and A53T (or ␤-gal or
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vector only) were introduced in a single electroporation just
24 h before the transport assay and the test protein expression was then amplified approximately threefold by using a
vaccinia virus vector encoding T7 RNA polymerase. Shift
from 40 to 32°C resulted in increasing conversion from GS to
GR VSV-G-myc, with complete conversion by 45 min (data
not shown). As seen in Figure 8A, A53T caused a trend
toward specific inhibition of conversion by 20 min and a
specific 23% inhibition of conversion by 30 min of transport,
relative to ␤-gal and vector controls. An example anti-VSVG-myc blot is shown in Supplemental Figure S4. Although
smaller in magnitude, these results confirm the more sensitive morphological assay (which by nature involves 100%
cotransfection and only includes cells that express A53T for
several days), demonstrating a delay in ER-to-Golgi transport in the presence of ␣-synuclein A53T.
There are numerous steps where ␣-synuclein could inhibit
VSV-G-myc transport before the mannosidase II modification that imparts endo H resistance. Due to the functional
antagonization of ER/Golgi SNAREs by ␣-synuclein (Figures 1–5), we explored whether at least part of the effects of
A53T on transport could be due to a direct effect on SNAREdependent docking and fusion. ER-to-Golgi cargo transport
must involve at least two membrane fusions: one fusion to
transfer cargo from COPII vesicles into vesicular tubular
clusters (VTCs) in the periphery of the cell and a second
fusion to transfer cargo from Golgi-centric VTCs into the
cis-Golgi (or alternatively to create the cis-Golgi de novo).
COPII vesicles in vitro contain all components necessary for
homotypic tethering and fusion to form nascent VTCs (Xu
and Hay, 2004; Bentley et al., 2006). Thus, homotypic COPII
vesicle fusion seems to represent at least one pre-Golgi
membrane fusion contributing to VTC biogenesis and anterograde transport. We used an established cell-free reconstitution of homotypic COPII vesicle fusion (Xu and Hay,
2004; Bentley et al., 2006; Yu et al., 2006; Cai et al., 2007) to
generate pre-Golgi intermediates resembling cellular VTCs.
Membrane fusion and contents mixing is scored biochemically by the heterotrimerization of radioactive VSV-G* with
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nonradioactive VSV-G-myc present initially in distinct COPII
vesicle populations. Heterotrimers are easily assayed by detergent solubilization of vesicles, immunoprecipitation using antimyc antibodies and autoradiography to detect the radioactive
subunits (Xu and Hay, 2004). As shown in Figure 8B, purified
bacterially expressed GST/␣-synuclein A53T (see Figure 9F for
a gel on the protein preparations used) inhibited heterotrimer
formation, whereas a preparation of GST purified in parallel
exhibited only a slight nonspecific inhibition at the highest
doses. Equal total protein amounts were compared, which
better accounts for nonspecific effects; the molar concentration
of ␣-synuclein at its 153-g dose is ⬃19 M. Thus, the inhibition occurs in a range compatible with the physiological
concentration of an abundant cytosolic protein. Interestingly, the inhibition is maximal at ⬃50%, reminiscent of the
incomplete inhibition of ER/Golgi transport, suggesting
perhaps that the fusion machinery may be only partially
inhibited by ␣-synuclein or sensitive during only one phase
of its life cycle. These results establish a direct effect of
␣-synuclein protein on the tethering/fusion machinery and
suggest that COPII vesicle docking and fusion is at least one
of the steps inhibited during A53T transfection experiments.
However, it does not rule out that other transport subreactions also could be directly or indirectly affected.

tion of the proteins. ␣-Synuclein, like unassembled SNARE
motifs, is a notably unstructured protein (Cookson and van
der Brug, 2008), which could easily lead to promiscuous
interactions and/or binding-induced deleterious structuring
of the SNARE motifs. Therefore, we preloaded bacterially
expressed GST-␣-syn A53T fusion protein or control GST
onto glutathione-Sepharose beads and tested the beads’
ability to capture and pull down the individual soluble
SNAREs. To increase the chances of detecting weak or transient binding, each soluble SNARE was tested at concentrations ranging up to and exceeding that at which nonspecific
binding to GST beads was observed. As shown in Figure 9A,
top two panels, and quantified in Figure 9B, both membrin
and syntaxin 5 were captured on GST-␣-syn A53T beads at
lower input concentrations and to a greater extent than on
GST beads, demonstrating a direct protein interaction with
␣-syn A53T. However, consistent with an inability to detect
solution-stable complexes (see below), these interactions
were not as robust as we have observed among ER/Golgi
SNAREs using the same binding technique (Xu et al., 2000).
Alternatively, we did not observe above-background interactions between GST-␣-syn A53T and rbet1 (Figure 9A, bottom). Unfortunately, sec22b binds Sepharose beads erratically in binding studies, making a positive outcome possible
only in cases of very strong specific binding. The erratic
nonspecific binding to beads made it impossible to determine whether weak binding was present (data not shown).
For the bead binding studies, consistent recovery of beads
and loading of samples is demonstrated in Supplemental
Figure S5A by ponceau staining of the same blot used in the
immunoblot analysis. Thus, at least a subset of the ER/Golgi
SNAREs, including membrin and syntaxin 5, directly interact with ␣-syn A53T, providing a potential basis for functional antagonization.
To test whether ␣-synuclein would impair membrin and
syntaxin 5 binding activities, we performed binary bead binding studies between these two SNAREs in the presence or
absence of soluble ␣-synuclein. As shown in Figure 9C, left
three lanes on the top panel, increasing soluble syntaxin 5 input
led to increased retention of syntaxin 5 on GST-membrin
beads. However, in the presence of soluble ␣-synuclein, the
same concentrations of soluble syntaxin 5 led to significantly
less binding to membrin (Figure 9C, top blot, right three lanes).
The presence of soluble ␣-synuclein A53T did not affect general
recovery or solubility of syntaxin 5, because the syntaxin 5
present in supernatants were virtually indistinguishable (Figure 9C, bottom blot). Addition of soluble GST and/or GST/␣synuclein A53T did not affect the amount of GST-membrin
immobilized on the recovered beads as indicated by ponceau
staining of the blot (Supplemental Figure S5B). Quantification
of two identical experiments, including control binding to GST
beads, is shown in Figure 9D. From the quantification, it can be
seen that ␣-synuclein reduced syntaxin 5–membrin binary interactions by approximately half. Formation of the physiological, fusogenic SNARE complex involving syntaxin 5, membrin, rbet1, and sec22b involves simultaneous interactions
between each one of the ER/Golgi SNAREs with the other
three. Partial suppression of several binary interactions each
involving syntaxin 5 and membrin could result in a dramatic
reduction in the yield of quaternary complex, causing a drastic
affect of ␣-synuclein A53T on trans-SNARE complex assembly.

␣-Synuclein A53T Directly Binds ER/Golgi SNAREs and
Impairs Their Interactions
One potential mechanism for the functional antagonization
of SNAREs by ␣-synuclein would involve a direct interac-

␣-Synuclein A53T Impairs SNARE 4-Helix Bundle
Formation
To test the possibility that ␣-synuclein might dramatically
inhibit formation of the ER/Golgi quaternary SNARE complex, we used an established SNARE complex assembly

Figure 8. (A) ␣-Synuclein inhibits transport before cargo modification by mannosidase II. NRK cells were electroporated with VSV-Gmyc DNA together with a construct for either ␤-galactosidase,
␣-synuclein A53T, or pcDNA3.1 vector alone. After 24 h, the cells were
infected with vaccinia virus vTF7 for 6 h at 40°C to amplify expression
(see Materials and Methods). Cells were either lysed directly (data not
shown) or shifted to 32°C for 20, 30, or 40 (data not shown) minutes
before lysis, digestion with endoglycosidase H, and immunoblotting
with anti-myc to detect VSV-G-myc. Histograms show GR as a percentage of GS ⫹ GR. Error bars show SE of duplicate gels run on the
same cell extracts. The same trends were observed in a completely
separate experiment with multiple time points. Supplemental Figure
S4 shows one of the immunoblots from which the data were quantified. (B) ␣-Synuclein A53T directly inhibits COPII vesicle fusion to
form pre-Golgi intermediates. Homotypic COPII vesicle fusion measured using the in vitro VSV-G heterotrimer cargo mixing assay. Purified proteins were added after vesicle budding and were incubated
with the budded vesicles for 1 h before a 1 h fusion reaction at 32°C.
“Ice” indicates heterotrimer signal obtained when the budded vesicles
were mixed but left on ice during the fusion incubation. Fusion assay
data are presented as means of duplicate determinations with error
bars representing SE where larger than symbol size.
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Figure 9. Soluble ␣-synuclein A53T protein
directly binds ER/Golgi SNAREs and inhibits
4-helix bundle assembly in vitro. (A) Glutathione beads preloaded with GST or GST-␣-syn
A53T were incubated with one of three concentrations of each individual purified, soluble
SNARE as indicated along the top edge of the
top panel (18 binding reactions in total). Beads
were washed extensively with buffer and then
analyzed by SDS-PAGE, ponceau staining, and
immunoblotting for bead-retained SNAREs using the antibodies listed along the left edge.
Ponceau staining for the same set of blots is
shown in Supplemental Figure S5A. (B) Quantitation of the binding experiment from A. (C)
Glutathione beads preloaded with GST-membrin were incubated with the soluble proteins
listed above the blots (see Materials and Methods for detailed conditions). After a 1-h binding incubation, beads were sedimented and
washed extensively. The presence of syntaxin 5
was determined by quantitative immunoblotting of the washed beads (top blot) and the supernatant from the first centrifugation (bottom
blot). (D) Quantification of bead-bound syntaxin
5 from two experiments like that shown in C.
Binding of syntaxin 5 to control GST beads is
also included, but for simplicity was not shown
in C. Error bars indicate SE where exceeding
symbol size. Ponceau stain of the blot in C can be
found in Supplemental Figure S5B. (E) Purified
soluble sec22b, syntaxin 5, membrin, and rbet1
were coincubated with either purified soluble
GST or GST/␣-syn A53T, as indicated with “⫹”
and “⫺” along right edge. After a 4-h ice incubation with all five purified proteins (see Materials and Methods for detailed conditions), the
mixture was fractionated by Superdex 200 chromatography. Selected column fractions, listed
along the top edge, were analyzed by SDS-PAGE and immunoblotting using the antibodies listed along the left edge. Positions of globular proteins
of known molecular size or blue dextran (“Vo”) are indicated with arrows above the fraction numbers. (F) Coomassie-stained SDS-PAGE gel
analysis of GST and GST/␣-syn A53T preparations in the same proportions used in the preincubations in parts C and E. An asterisk marks the
␣-syn A53T protein band.

assay involving purified, soluble versions of syntaxin 5,
membrin, rbet1, and sec22b (Xu et al., 2000; Joglekar et al.,
2003; Joglekar and Hay, 2005). In this assay, the four soluble
SNARE constructs are incubated together on ice to allow
assembly into a SNARE complex and then gel filtered to
separate assembled species from remaining individual components. The ER/Golgi quaternary complex elutes in fractions corresponding to globular markers of⬃250 kDa and
contains all of the SNARE motifs of the input SNAREs in the
stoichiometry 1Qa:1Qb:1Qc:1R. Although the calculated molecular mass of the quaternary complex is 85 kDa, its oligomerization state, overall rod-like shape, and an unknown
amount of bound detergent contribute to its elution in
higher molecular mass gel filtration fractions (Xu et al.,
2000). Formation of four-helix bundles with this structural
organization is highly conserved among SNAREs and seems
to represent the thermodynamic engine for membrane fusion. Indeed, formation of the yeast version of the ER/Golgi
quaternary complex causes lipid and content mixing of purified synthetic vesicles (McNew et al., 2000). In vitro, sec22b
will not assemble into any solution-stable species except the
quaternary complex containing all four ER/Golgi SNAREs
(Xu et al., 2000). Due to this remarkable cooperativity, assembly of the full ER/Golgi quaternary complex can be
monitored in gel filtration simply by monitoring the elution
of a single protein—sec22b—as it shifts from its monomer
Vol. 21, June 1, 2010

peak at ⬃25 kDa (fractions 26 –34) to the quaternary complex
peak at ⬃225 kDa (fractions 16 –18). All of the sec22b in
fractions 16 –18 is part of a quaternary complex containing
all four ER/Golgi SNAREs (Xu et al., 2000).
GST or GST/␣-syn A53T were mixed in approximately
threefold molar excess with the purified ER/Golgi SNAREs.
SNARE complex assembly was allowed to proceed, in the
presence of GST or GST/␣-syn, for 4 h, and then the protein
mixtures were gel filtered by Superdex 200 chromatography.
As shown in Figure 9E, top, a portion of sec22b was able to
assemble with the other SNAREs into the quaternary
SNARE complex present in fractions 16 –18, after a control
preincubation with GST. The relatively small proportion of
sec22b assembled was not significantly different from when
GST was omitted (data not shown) and is typical for the
time, temperature, and SNARE preparations used (Xu et al.,
2000; Joglekar et al., 2003; Joglekar and Hay, 2005). Strikingly, we found that the inclusion of GST/␣-syn A53Twith
the SNAREs blocked elution of sec22b in fractions 16 –18
(Figure 9E, second panel). Conversely, the amount of total
sec22b recovered in the column fractions did not change
significantly from the control, and sec22b eluted overwhelmingly in the monomer fractions (26 –34), demonstrating that ␣-syn A53T did not seem to cause aggregation,
sequestration into nonproductive complexes, nor significant
loss of sec22b during our analysis. We conclude that ␣-syn
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A53T blocked quaternary complex formation and caused
sec22b to remain unassembled. These results were consistent
over numerous repetitions and with several batches of proteins (data not shown). Supplemental Figure S5C shows
subsaturating exposures of immunoblots of the soluble protein mixtures injected onto gel filtration in Figure 9E. Although there are relatively small variations in soluble protein after the incubations that could be due to ␣-syn A53T
(e.g., by effects on adsorption of proteins to plastic surfaces),
these small differences could not explain the decisive and
selective effects seen on quaternary complex formation.
The ␣-syn A53T present in the SNARE mixture eluted at a
low molecular mass (Figure 9E, bottom, fraction 30), consistent with it being a monomer of an unstructured protein
with a slightly larger tumbling radius than its molecular
mass of 14.5 kDa would predict. No aggregated ␣-syn A53T
in the void (fractions 6 – 8) nor solution-stable ␣-syn-SNARE
complexes were apparent by gel filtration. We conclude that
soluble, low-molecular-mass ␣-syn A53T prevented ER/
Golgi quaternary SNARE complex assembly via a direct
effect on SNARE interactions. Solution binding studies, especially involving the greater dilution and time during a gel
filtration step, present more stringent conditions for binding
than the GST pull downs where fusion proteins are highly
concentrated on a bead surface. The SNARE-␣–synuclein
interactions detected in bead-biding studies in Figure 9, A
and B, may have been too weak or transient to be evident by
gel filtration, whereas their effects on assembly of the quaternary SNARE complex, a solution-stable species, were
clearly apparent.
DISCUSSION
Despite important differences in the role of aggregation
phenomena between the yeast and our studies, our data are
consistent with the recently proposed hypothesis that inhibition of ER/Golgi transport is the initiating and most fundamental cellular toxicity of ␣-synuclein (Cooper et al., 2006;
Hamamichi et al., 2008). That ␣-synuclein protein acts directly on the transport machinery is supported by multiple
observations of this study: 1) ␣-syn A53T maximally inhibits
transport at low expression levels and in the absence of any
apparent cytopathic effects, detergent-insoluble aggregates,
mistargeting or coaggregation of transport machinery; 2)
coexpression of ␣-syn A53T with ER/Golgi SNAREs
nearly completely overcomes the transport delay, but these
SNAREs do not in and of themselves accelerate ER-to-Golgi
transport, nor alter ␣-synuclein expression, aggregation or
disposal, indicating that transport restoration occurs by replacement of SNAREs incapacitated by ␣-synuclein; 3) soluble ␣-syn A53T protein directly inhibits SNARE-dependent
COPII vesicle docking and fusion at a pre-Golgi step in vitro;
4) soluble ␣-syn A53T binds ER/Golgi SNAREs and inhibits
formation of the fusogenic 4-helix bundle required for the
earliest step(s) in the secretory pathway.
Although our data are compatible with a toxicity-initiating role for the inhibition of ER/Golgi transport in PD
(Cooper et al., 2006), many other cytotoxicities (Cookson and
van der Brug, 2008) may subsequently occur as domino
effects—some of which may actually be more disruptive to
neurons. Consistent with our mild overexpression conditions, we noted no cytopathic effects of A53T expression
using the pcDNA3.1 vector for several days. On the other
hand, relatively mild secretory delays could cause tissueand cell type-specific diseases where highly efficient ER/
Golgi transport is needed for extracellular matrix deposition
(Townley et al., 2008) or compartmentation of dopamine
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(Cooper et al., 2006). Furthermore, even if delayed ER/Golgi
transport does not itself harm cells, the resulting unfolded
protein response would eventually cause toxicity (Sugeno et
al., 2008).
Although the results in Figure 9E clearly show that
␣-synuclein A53T directly inhibited ER/Golgi quaternary
SNARE complex assembly, they do not distinguish which
specific step in assembly was inhibited and which particular
assembly intermediates failed to form. The inhibition of
SNARE complex assembly seen in Figure 9E could be caused
by weak or transient ␣-synuclein interactions with one, two,
or more of the four ER/Golgi SNAREs. ␣-synuclein A53T
may transiently bind the SNARE motifs to perturb their
structure and/or compete with other SNAREs for binding.
No evidence for a SNARE sequestering or coaggregation
mechanism for the ␣-syn A53T effect was found, because in
the gel filtration experiments, ␣-synuclein always behaved
as a low molecular weight species with a sharp elution, even
in the presence of the inhibited ER/Golgi SNAREs (Figure
9E, bottom).
A previous report found that the endogenous function of
␣-synuclein in the synapse may be to cooperate with the
synaptic vesicle chaperone cysteine string protein to somehow protect or maintain SNARE activity (Chandra et al.,
2005). Interestingly, our studies indicate that excess or mutant ␣-synuclein has the opposite effect on the ER/Golgi
SNAREs. We can only speculate that in the synapse, there
are other cellular factors, one possibility being cysteine
string protein, that allow␣-synuclein to carry out a positive function in membrane docking and/or fusion. In the
early secretory pathway, in the absence of synaptic cochaperones, ␣-synuclein may exhibit an activity that slows
the analogous step(s) in docking and fusion. Thus, normal
neurons expressing ␣-synuclein may be in a delicate balance
between supporting synaptic function and slowing the biosynthetic secretory pathway through disruption of ER/
Golgi SNAREs. Overexpression or mutation of ␣-synuclein
may simply amplify the negative features of this normal
cellular trade-off.
Other reports from the synapse argue for a regulatory role
of ␣-synuclein upstream of docking in the maintenance of
the readily releasable pool of synaptic vesicles (Fortin et al.,
2005; Larsen et al., 2006). Too much ␣-synuclein would lead
to a decreased vesicle reclustering after endocytosis and
decreased releasable vesicle pool (Nemani et al., 2010). This
inhibitory role of ␣-synuclein overexpression could be completely independent of it’s effects on SNAREs and the biosynthetic secretory pathway; alternatively, one could imagine how it could arise as an indirect consequence of altered
biosynthetic transport of membrane proteins to the plasma
membrane or endosomes. For example, due to decreased
biosynthetic delivery and/or replenishment rates, key synaptic vesicle trafficking machinery may be present at lower
abundance in the synapse, rendering the reclustering of
vesicles less efficient. Though a few synaptic proteins were
examined and found to be present at wild-type levels
(Nemani et al., 2010), the variable trafficking itineraries, recycling and turnover rates of distinct membrane proteins in
the synapse makes it nearly impossible to exclude that
slowed ER-to-Golgi transport altered the abundance of key
proteins affecting vesicle replenishment.
What properties of ykt6 might make it a more potent
suppressor of the transport defect? One possibility is that
because ykt6 normally participates in several membrane
fusion complexes, it possesses a greater functional flexibility
that makes it a superior suppressor of ER-to-Golgi transport,
which involves multiple distinct fusion complexes. Another
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possibility is that because ykt6 may be able to target to sites
of function directly from the cytosol (Fukasawa et al., 2004),
rather than by transport through the secretory pathway, it
may be better suited to restoring function to membranes that
would be otherwise unreachable–in other words, ykt6 could
be acting as a SNARE smoke jumper. Although our results
do not prove that ykt6 expression is naturally elevated in
neurons because ␣-synuclein is present in those tissues, it
does suggest at least one side benefit of this overexpression—a more robust early secretory pathway.
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Söllner, T. H., and Rothman, J. E. (2000). Compartmental specificity of cellular
membrane fusion encoded in SNARE proteins. Nature 407, 153–159.
Mezzacasa, A., and Helenius, A. (2002). The transitional ER defines a boundary for quality control in the secretion of tsO45 VSV glycoprotein. Traffic 3,
833– 849.
Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K.,
Chaudhry, F. A., Nicoll, R. A., and Edwards, R. H. (2010). Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66 –79.

Cai, H., Yu, S., Menon, S., Cai, Y., Lazarova, D., Fu, C., Reinisch, K., Hay, J. C.,
and Ferro-Novick, S. (2007). TRAPPI tethers COPII vesicles by binding the
coat subunit Sec23. Nature 445, 941–944.

Rossi, V., Banfield, D. K., Vacca, M., Dietrich, L. E., Ungermann, C.,
D’Esposito, M., Galli, T., and Filippini, F. (2004). Longins and their longin
domains: regulated SNAREs and multifunctional SNARE regulators. Trends
Biochem. Sci. 29, 682– 688.

Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O. M., and Südhof,
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